Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Security class unavailable · CUSIP: 05338F108

Event date: 2022-07-25

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
798,258
Percent of class
8.4900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001929354-22-000004
Form type
SC 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
Aug 08, 2022
Reporting period
Jul 25, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub